BELRAPZO - (25 mg/ml; Solution, IV (Infusion))

Generic Name	BENDAMUSTINE HYDROCHLORIDE	**Innovator**	Eagle
Dosage	25 mg/ml; Solution, IV (Infusion)	**Branded US Sales**	Less Than $1000 mn
Probable FTF	Less Than 5	**Known Para IV Filers**	More Than 5
Other ANDA developers	Less Than 5	**Tentative Approvals**	Less Than 5
Final Approvals	Less Than 5	**Generic Launches**	Less Than 5
Indication	Indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.